Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PROK

PROK - ProKidney Corp. Stock Price, Fair Value and News

$2.12-0.09 (-4.07%)
Market Closed

30/100

PROK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

30/100

PROK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.74

Target 3M

$2.03

Target 6M

$1.9

PROK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PROK Price Action

Last 7 days

-1.4%

Last 30 days

-3.6%

Last 90 days

-31.2%

Trailing 12 Months

30.9%

PROK RSI Chart

PROK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PROK Valuation

Market Cap

623.9M

Price/Earnings (Trailing)

-8.78

Price/Sales (Trailing)

38.91

EV/EBITDA

-3.54

Price/Free Cashflow

-4.25

PROK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.74

Target 3M

$2.03

Target 6M

$1.9

PROK Fundamentals

PROK Revenue

Revenue (TTM)

20.5M

Rev. Growth (Yr)

-41.61%

Rev. Growth (Qtr)

-13.57%

PROK Earnings

Earnings (TTM)

-71.0M

Earnings Growth (Yr)

8.05%

Earnings Growth (Qtr)

0.5%

PROK Profitability

EBT Margin

-758.93%

Return on Equity

7.05%

Return on Assets

-20.2%

Free Cashflow Yield

-23.52%

PROK Investor Care

Shares Dilution (1Y)

1.59%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202421.6M20.2M20.2M19.8M
202311.6M17.2M21.2M22.1M
2022004.8M6.0M
202101.2M2.4M3.6M
202000043.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About ProKidney Corp.

PROK
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
 CEO
 WEBSITEprokidney.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES87

ProKidney Corp. Frequently Asked Questions

PROK is the stock ticker symbol of ProKidney Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ProKidney Corp. is 623.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PROK's fair value in chart for subscribers.

The fair value guage provides a quick view whether PROK is over valued or under valued. Whether ProKidney Corp. is cheap or expensive depends on the assumptions which impact ProKidney Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PROK.

As of Wed Jan 28 2026, PROK's PE ratio (Price to Earnings) is -8.78 and Price to Sales (PS) ratio is 38.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PROK PE ratio will change depending on the future growth rate expectations of investors.